Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
The Northeast Science and Technology Center in New Jersey is transforming into a major biotech hub through a strategic partnership. ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
Cleveland Clinic and IBM join forces to advance immunotherapy research through AI, unlocking new targets for cancer therapy. #Immunotherapy #AI ...
Large language models (LLMs) can effectively extract information on social determinants of health (SDoH) from clinicians' notes, improving patient care ...
Goldman Sachs Asset Management launches a $650M life sciences fund, focusing on growth-oriented private equity investments in early- to mid-stage ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.